Guardant Health Director Alex M. Azar II Files Form 144 for Routine Share Sale
Guardant Health, Inc.
Subscribe to track GH
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
Proposed sale of 69 shares of Guardant Health, Inc. ($GH) common stock valued at approximately $11,032 by Director Alex M. Azar II under a Rule 10b5-1 trading plan adopted on May 21, 2026.
Comprehensive Analysis
Overview
On October 14, 2026, Guardant Health, Inc. ($GH) director Alex M. Azar II filed a Form 144 notice proposing the sale of 69 shares of common stock through Charles Schwab & Co., Inc., with an aggregate market value of approximately $11,032.
Transaction Details
- Securities to be Sold: 69 shares of Common Stock.
- Aggregate Market Value: $11,032.00 (implied price of ~$159.88 per share).
- Acquisition Origin: The shares were acquired on October 12, 2026, through a restricted stock lapse as part of standard equity compensation.
- Trading Plan: The proposed transaction is scheduled pursuant to a Rule 10b5-1 trading plan established on May 21, 2026.
- Prior Sales: In the past three months, Mr. Azar sold 826 shares on September 16, 2026, generating gross proceeds of $144,550.00.
Market Impact & Significance
This filing carries Low trading significance due to the nominal share volume (69 shares) and dollar value ($11,032) relative to Guardant Health's total outstanding shares (134,196,170). The sale reflects routine liquidation following equity vesting under a pre-established 10b5-1 plan.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.